
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TIVICAY PD | ViiV Healthcare | N-213983 RX | 2020-06-12 | 1 products, RLD, RS |
| TIVICAY | ViiV Healthcare | N-204790 RX | 2013-08-12 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIUMEQ PD | ViiV Healthcare | N-215413 RX | 2022-03-30 | 1 products, RLD, RS |
| TRIUMEQ | ViiV Healthcare | N-205551 RX | 2014-08-22 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOVATO | ViiV Healthcare | N-211994 RX | 2019-04-08 | 1 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JULUCA | ViiV Healthcare | N-210192 RX | 2017-11-21 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| dolutegravir | Export only | 2021-03-05 |
| dovato | New Drug Application | 2024-04-18 |
| juluca | New Drug Application | 2024-04-18 |
| tivicay | New Drug Application | 2024-07-18 |
| tivicay tivicay pd | New Drug Application | 2024-04-18 |
| triumeq | New Drug Application | 2021-03-23 |
| triumeq triumeq pd | New Drug Application | 2024-07-08 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hepatitis b | — | D006509 | — |
Expiration | Code | ||
|---|---|---|---|
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ, VIIV HLTHCARE | |||
| 2026-12-15 | PED | ||
| 2026-06-15 | M-294 | ||
ABACAVIR SULFATE / DOLUTEGRAVIR SODIUM / LAMIVUDINE, TRIUMEQ PD, VIIV HLTHCARE | |||
| 2026-12-15 | PED | ||
| 2026-06-15 | NPP | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Dolutegravir Sodium / Rilpivirine Hydrochloride, Juluca, Viiv Hlthcare | |||
| 10426780 | 2031-01-24 | DS, DP | U-257 |
| 7125879 | 2025-04-21 | DS, DP | U-257 |
| Dolutegravir Sodium / Lamivudine, Dovato, Viiv Hlthcare | |||
| 11234985 | 2031-01-24 | DP | U-257 |
| Abacavir Sulfate / Dolutegravir Sodium / Lamivudine, Triumeq, Viiv Hlthcare | |||
| 9242986 | 2029-12-08 | DS, DP | |
| 8129385 | 2027-10-05 | DS, DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 38 | 15 | 32 | 16 | 12 | 110 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 32 | 4 | 15 | 4 | 5 | 60 |
| Infections | D007239 | EFO_0000544 | — | 29 | 3 | 15 | 1 | 5 | 53 |
| Hiv | D006678 | — | O98.7 | 4 | 1 | 5 | 9 | 2 | 20 |
| Communicable diseases | D003141 | — | — | 3 | — | 8 | 1 | 2 | 14 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | 2 | 2 | — | 4 |
| Coinfection | D060085 | — | — | — | — | 1 | 1 | — | 2 |
| Papillomaviridae | D027383 | — | — | — | — | — | 1 | — | 1 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | 1 | — | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | 1 | 2 | — | 1 | 5 |
| Breast feeding | D001942 | — | — | — | 1 | 1 | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | 1 | — | — | 1 |
| Arthralgia | D018771 | — | M25.5 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Malaria | D008288 | EFO_0001068 | B54 | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Persistent infection | D000088562 | — | — | — | — | — | — | 1 | 1 |
| Drug common name | Dolutegravir |
| INN | dolutegravir |
| Description | Dolutegravir is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of (4R,12aS)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid with the amino group of 2,4-difluorobenzylamine. Used (as its sodium salt) for treatment of HIV-1. It has a role as a HIV-1 integrase inhibitor. It is a monocarboxylic acid amide, an organic heterotricyclic compound, a secondary carboxamide and a difluorobenzene. It is a conjugate acid of a dolutegravir(1-). |
| Classification | Small molecule |
| Drug class | antivirals: integrase inhibitors |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21 |
| PDB | — |
| CAS-ID | 1051375-16-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1229211 |
| ChEBI ID | 76010 |
| PubChem CID | 54726191 |
| DrugBank | DB08930 |
| UNII ID | DKO1W9H7M1 (ChemIDplus, GSRS) |

